These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22032054)

  • 21. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
    Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
    Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry.
    Liistro F; Fineschi M; Angioli P; Sinicropi G; Falsini G; Gori T; Ducci K; Bravi A; Bolognese L
    J Am Coll Cardiol; 2006 Jul; 48(2):270-5. PubMed ID: 16843174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation.
    Hikita H; Sato A; Nozato T; Kawashima T; Takahashi Y; Kuwahara T; Takahashi A
    Scand Cardiovasc J; 2009; 43(5):298-303. PubMed ID: 19263268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of sirolimus-eluting stent implantation in diabetic patients with very small vessels (< or = 2.25 mm). Insights from the DIABETES trial].
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; Gómez-Hospital JA; Sanmartín M; Bañuelos C; Moreno R; Escaned J; Fernández C; Costa MA; Fernández-Avilés F; Macaya C
    Rev Esp Cardiol; 2006 Oct; 59(10):1000-7. PubMed ID: 17125709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late restenosis following sirolimus-eluting stent implantation.
    Kuriyama N; Kobayashi Y; Nakama T; Mine D; Nishihira K; Shimomura M; Nomura K; Ashikaga K; Matsuyama A; Shibata Y
    JACC Cardiovasc Interv; 2011 Jan; 4(1):123-8. PubMed ID: 21251639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: results of long-term follow-up.
    Freixa X; Almasood AS; Khan SQ; Wainstein R; Osherov A; Mackie K; Seidelin PH; Džavík V
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):559-65. PubMed ID: 21567881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients.
    Kawaguchi R; Tsurugaya H; Hoshizaki H; Toyama T; Oshima S; Taniguchi K
    Cardiovasc Revasc Med; 2008; 9(1):2-8. PubMed ID: 18206630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crush stenting with paclitaxel-eluting or sirolimus-eluting stents for the treatment of coronary bifurcation lesions.
    Chen S; Zhang J; Ye F; Zhu Z; Lin S; Tian N; Liu Z; Fang W; Chen Y; Sun X; Kwan TW
    Angiology; 2008; 59(4):475-83. PubMed ID: 18388098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era.
    Iijima R; Ndrepepa G; Mehilli J; Markwardt C; Bruskina O; Pache J; Ibrahim M; Schömig A; Kastrati A
    Am Heart J; 2007 Oct; 154(4):688-93. PubMed ID: 17892992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents.
    Mauri L; O'Malley AJ; Popma JJ; Moses JW; Leon MB; Holmes DR; Teirstein PS; Cutlip DE; Donahoe D; Kuntz RE
    Am J Cardiol; 2005 May; 95(10):1140-5. PubMed ID: 15877983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
    Holmes DR; Teirstein P; Satler L; Sketch M; O'Malley J; Popma JJ; Kuntz RE; Fitzgerald PJ; Wang H; Caramanica E; Cohen SA;
    JAMA; 2006 Mar; 295(11):1264-73. PubMed ID: 16531619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial.
    Maeng M; Jensen LO; Galloe AM; Thayssen P; Christiansen EH; Hansen KN; Helqvist S; Botker HE; Lassen JF; Thuesen L
    Am J Cardiol; 2009 Feb; 103(3):345-9. PubMed ID: 19166687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.